Drug intelligence / Profile preview

VT400X + VT500X

Development stage: Preclinical
Lead developer: Vigeo Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

VT400X + VT500X is a pair of preclinical monoclonal antibody programs being developed by Vigeo Therapeutics for the treatment of various cancers. These antibodies are designed to target PRSS2 (trypsinogen-2) and other novel, undisclosed targets to reprogram the tumor immune microenvironment (TIME). The development of these assets leverages Vigeo's expertise in thrombospondin-1 (TSP-1) biology, aiming to overcome immune suppression within the tumor and enhance anti-tumor immunity. As of 2024, both programs remain in the preclinical stage of development.

Targets

PRSS2 (Trypsin-2)

Beyond the preview

Go deeper on VT400X + VT500X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VT400X + VT500X.

Explore the full profile